Acute myocarditis after COVID-19 vaccination

Area of Science:

• Cardiology
• Immunology
• Public Health

Background:

• Reports indicate a significant increase in heart inflammation cases following SARS-CoV-2 messenger RNA (mRNA) vaccination.
• Adverse effects, including myopericarditis, have been noted as a potential risk associated with COVID-19 vaccination.
• The Disease Control Centers in America have documented these occurrences, highlighting a rise since April 2021.

Purpose of the Study:

• To present a case study of myopericarditis following mRNA-1273 vaccine administration.
• To discuss the clinical presentation and management of vaccine-associated myopericarditis.
• To emphasize the importance of early diagnosis in managing potential cardiac complications post-vaccination.

Main Methods:

• Case report of an 18-year-old male presenting with chest pain post-mRNA-1273 vaccination.
• Clinical evaluation including troponin levels and electrocardiogram (ECG) changes.
• Exclusion of other infectious or immune causes for the observed symptoms.

Main Results:

• The patient exhibited chest pain, elevated troponin levels, and new-onset ECG changes consistent with myopericarditis.
• The patient's hemodynamic status remained stable throughout hospitalization.
• No alternative infectious or immune etiologies were identified.

Conclusions:

• While mRNA COVID-19 vaccines offer significant benefits, a potential risk of myopericarditis exists.
• Prompt diagnosis and management are essential for addressing morbidity and mortality associated with vaccine-associated myopericarditis.
• The benefits of SARS-CoV-2 vaccination are considered to outweigh the identified risks.